<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00297193</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT2005-003337-40</org_study_id>
    <secondary_id>ASTIC</secondary_id>
    <nct_id>NCT00297193</nct_id>
  </id_info>
  <brief_title>ASTIC Autologous Stem Cell Transplantation for Crohn's Disease</brief_title>
  <official_title>Autologous Stem Cell Transplantation for Crohn's Disease: ASTIC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Group for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Broad Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Group for Blood and Marrow Transplantation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transplant study for patients with relapsing Crohn's disease demonstrating clear intolerance
      or toxicity to conventional treatment.

      The purpose of this study is to determine whether there is a potential clinical benefit of
      hematopoietic stem cell mobilisation followed by high dose immuno-ablation and autologous
      stem cell transplantation versus hematopoietic stem cell mobilisation only followed by best
      clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, phase III, randomised, multicentre study comparing early transplantation
      procedure with transplantation carried out to the same protocol but delayed by one year. The
      status of patients undergoing early HSCT will be evaluated after one year and compared to
      those about to undergo delayed HSCT

      Patients will be randomised to:

        -  Hematopoietic stem cell mobilisation followed, within 4 weeks, by high dose
           immunoablation and autologous stem cell transplantation

        -  Hematopoietic stem cell mobilisation followed, after 59 weeks, by high dose
           immunoablation and autologous hematopoietic stem cell transplantation

      All patients will be mobilised prior to randomisation. Those receiving early transplantation
      will be compared over the first year with those whose transplant has been delayed.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    For safety reasons the recruitment was halted prematurely. Patients on the trial continute to
    receive treatment and are being followed up as part the protocol.
  </why_stopped>
  <start_date>June 2006</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion patients in sustained disease remission</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the potential clinical benefit of hematopoietic stem cell mobilisation followed by high dose immuno-ablation and autologous stem cell transplantation versus hematopoietic stem cell mobilisation only followed by best clinical practice in patients with Crohn' s disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patients who have not responded to immunosuppressant medication</measure>
    <time_frame>1 - 2 years</time_frame>
    <description>To evaluate the safety of Hematopoietic Stem Cell Transplantation (HSCT) in Crohn's disease patients who have not responded to immunosuppressant medication</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Impact of HSCT on health related, and generic, quality of life measures</measure>
    <time_frame>1 - 2 Years</time_frame>
    <description>To evaluate the impact of HSCT on health related, and generic, quality of life measures</description>
  </other_outcome>
  <other_outcome>
    <measure>To identify factors predictive of success</measure>
    <time_frame>1-2 years</time_frame>
    <description>To identify factors predictive of success</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Transplant Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hematopoietic stem cell mobilisation followed, within 4 weeks, by high dose immunoablation and autologous stem cell transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hematopoietic stem cell mobilisation followed, after 59 weeks, by high dose immunoablation and autologous hematopoietic stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous haematopoietic stem cell transplant</intervention_name>
    <description>All patients will be mobilised prior to randomisation. Those receiving early transplantation will be compared over the first year with those whose transplant has been delayed.</description>
    <arm_group_label>Transplant Arm</arm_group_label>
    <arm_group_label>Delayed Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria: mandatory

          1. Age between 18 and 50 years (Patients aged 50-65 can participate if specially approved
             by the Trial Steering Committee)

          2. Confirmed diagnosis of active Crohn's Disease

          3. Unsatisfactory course despite 3 immunosuppressive agents (usually azathioprine,
             methotrexate and infliximab) in addition to corticosteroids. Patients should have
             relapsing disease (i.e. &gt;1 exacerbation/year) despite thiopurines, methotrexate and/or
             infliximab maintenance therapy or clear demonstration of intolerance / toxicity to
             these drugs.

          4. Impaired function and quality of life, compared to population means, on at least one
             of the following:

               1. IBDQ (Appendix 6)

               2. European Questionnaire of Life quality (EuroQOL-5D, Appendix 4)

               3. Impaired function on Karnofsky index (Appendix 7)

          5. Current problems unsuitable for surgery and patient at risk for developing short bowel
             syndrome.

          6. Informed consent

        Inclusion criteria: discretionary

          1. Wherever possible, diseased tissue should be accessible endoscopically for objective
             histological study but in the case of small bowel disease that is extensive but does
             not extend to duodenum or terminal ileum, participation without endoscopy is allowed.

          2. Smokers may enter the study provided they have received intensive counselling about
             smoking.

          3. Add patients with ileostomy/colostomy and patients with short bowel syndrome

        Exclusion Criteria:

          1. Pregnancy or unwillingness to use adequate contraception during the study

          2. Concomitant severe disease

          3. Diarrhoea due to short small or large bowel

          4. Infection or risk thereof

          5. Significant malnutrition: Body Mass Index (BMI) ≤18, serum albumin &lt;20 g/l

          6. Previous poor compliance

          7. Concurrent enrolment in any other protocol using an investigational drug or
             hematopoietic growth factor up to four weeks before study entry.

          8. Lack of funding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher J Hawkey</last_name>
    <role>Study Chair</role>
    <affiliation>Nottingham University Hospital - Wolfson Digestive Diseases Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <state>Herestraat 49</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgery</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Huriez Chru</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sanin-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipatimento di Medicina Interna E Gastroenterologia</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Bologna Interna e Gastroenterologia Policlinico Saint Orsola</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Careggi Hospital</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Milan</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L Sacco University Hopsital</name>
      <address>
        <city>Milan</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa Sollievo Della Sofferenza IRCCS Hospital</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias I Pujol, Dept of Gastroenterology</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Headington</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts and the London NHS Trust</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham Digestive Diseases Centre</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </removed_countries>
  <link>
    <url>http://www.nottingham.ac.uk/icr/astic/</url>
    <description>Trial Website</description>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2006</study_first_submitted>
  <study_first_submitted_qc>February 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2006</study_first_posted>
  <last_update_submitted>August 29, 2013</last_update_submitted>
  <last_update_submitted_qc>August 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <keyword>HSCT</keyword>
  <keyword>Autologous</keyword>
  <keyword>EBMT</keyword>
  <keyword>ECCO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

